We are a clinical stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. We leverage our expertise in superoxide dismutase mimetics to design drugs with the potential to reduce normal tissue toxicity from radiotherapy and to increase the anti-cancer efficacy of radiotherapy.
Our lead product candidate, avasopasem (GC4419), is a highly selective small molecule dismutase mimetic we are initially developing for the reduction of severe oral mucositis (SOM). SOM is a common, debilitating complication of radiotherapy in patients with head and neck cancer. The U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to avasopasem for the reduction of the duration, incidence and severity of SOM induced by radiotherapy. Avasopasem is currently in Phase 3 clinical testing.
We believe avasopasem, which to date is not approved for any indication, has the potential to be the first FDA-approved drug and the standard of care for the reduction of SOM in patients with head and neck cancer receiving radiotherapy, and we plan to further evaluate its use in other radiotherapy-induced toxicities.
J. Mel Sorensen, MD
President and Chief Executive Officer
Dr. Sorensen has served as Director, Chief Executive Officer and President of Galera since 2012.
Dr. Sorensen serves on the board of several private biopharmaceutical companies, as director or Chairman, including Oncopia Therapeutics, OncoFusion Therapeutics, Esanik Therapeutics and Context Therapeutics. He is an advisor to the Biomarkers Consortium of the National Institutes of Health and to the Irish Cancer Society.
Dr. Sorensen holds an M.B., B.Ch. and B.A.O. from University College, Dublin. Dr. Sorensen’s postgraduate education and work has been in the United States, including an internal medicine residency in St. Louis and medical oncology fellowship at the Mayo Clinic, seven years at the National Cancer Institute as Senior Investigator in the Cancer Therapy Evaluation Program and four years each with Bayer and GlaxoSmithKline. Dr. Sorensen served as Director, Chief Executive Officer and President of Ascenta Therapeutics from 2004 until he joined Galera.
Robert A. Beardsley, PhD
Chief Operating Officer
Dr. Beardsley, a co-founder of the Company, has served as our Chief Operating Officer since 2015, and from 2012 to 2017 as our Executive Chair.
Prior to this, Dr. Beardsley was the Chief Executive Officer at Galera Therapeutics, LLC from 2010 to 2012, at Metabolic Solutions Development Corporation from 2009 until 2010, and at Kereos from 2003 until 2009, and the acting Chief Executive Officer at Metaphore Pharmaceuticals, Inc. in 2002. He has also served in various management roles at Confluence Life Sciences, bioStrategies Group, Vector Securities International, Enzyme Organics and Mobil Oil. Dr. Beardsley has served on a number of public and private boards including Euclises, Epigenetx, KemPharm, Kereos, CollaGenex Pharmaceuticals, Bioseek, and Metaphore Pharmaceuticals.
Dr. Beardsley received a B.S. in Chemical Engineering, a Ph.D. in Biochemical Engineering from the University of Iowa and an M.B.A. in Finance from the University of Chicago.
Dennis P. Riley, PhD
Chief Scientific Officer
Dr. Riley co-founded Galera Therapeutics and has been Galera’s CSO since the founding.
Prior to Galera Therapeutics, Dr. Riley was Senior Vice President at Kereos and prior to that was VP of Research at Metaphore Pharmaceuticals. Dr. Riley spent much of his career at Monsanto, rising to a Senior Science Fellow and Manager of Metal-Mediated Chemistry. Dr. Riley is an Adjunct Professor of Chemistry at Washington University.
After graduating cum laude from Heidelberg College with majors in chemistry and mathematics, he earned his PhD at Ohio State University followed by post-doctoral training at the University of Chicago. He was elected a Fellow of the American Association for the Advancement of Science in 1996, elected Chairperson and organizer of the 1998 Gordon Research Conference on Inorganic Chemistry, was the recipient of the ACS St. Louis Section’s “Chemist of the Year” Award for 1999, was the recipient of the 2002 Ohio State University Devon Meek Memorial Lectureship, is the recipient of the 2003 Herman S. Bloch memorial lectureship at the University of Chicago, and was lecturer at the 31st Peter A. Leermakers symposium at Wesleyan University in May 2003. He has over 30 US Patents granted, and has published over 100 primary scientific articles.
Jon T. Holmlund, MD
Chief Medical Officer
Dr. Holmlund is a medical oncologist who has served Galera as Chief Medical Officer since October 2012.
He has over 25 years’ experience in oncology drug development, in senior positions in industry (CMO of Ascenta Therapeutics, VP of Development at Isis [now Ionis] Pharmaceuticals), as a consultant to large and small biopharmaceutical companies, and as a senior investigator in the National Cancer Institute’s Cancer Therapy Evaluation Program and Biological Response Modifiers Program.
He received his MD from SUNY Buffalo and completed postgraduate training in internal medicine and medical oncology at George Washington University Medical Center (Washington, DC).
Arthur Fratamico, RPh
Chief Business Officer
Mr. Fratamico is a registered pharmacist with over 25 years of experience in the pharmaceutical industry and has been our Chief Business Officer since January 2017.
Prior to joining Galera, Mr. Fratamico served as Chief Business Officer of Vitae Pharmaceuticals until its sale to Allergan. Prior to Vitae Pharmaceuticals, he has held similar executive roles with a number of biotechnology companies leading their business development efforts, including facilitating the sales of Gemin X Pharmaceuticals and MGI Pharma.
In addition to being responsible for numerous licensing transactions and acquisitions, he also directed corporate strategy and managed external corporate communications. He also served in several senior marketing, product planning and new product development positions. Mr. Fratamico earned a bachelor’s degree in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from Drexel University.
Chief Financial Officer
Mr. Degnan has served as our Chief Financial Officer since October 2019.
Prior to Galera, Mr. Degnan served as Chief Financial Officer of Verrica Pharmaceuticals Inc. In his role at Verrica, Mr. Degnan successfully completed an initial public offering raising gross proceeds of $86 million, and has extensive experience in financial strategy, investor relations, U.S. Securities and Exchange Commission reporting, accounting and compliance. Previously, Mr. Degnan held senior positions at Endo International plc, a generics and specialty branded pharmaceutical company, most recently as Vice President of Finance, Corporate FP&A and International Pharmaceuticals Segment Chief Financial Officer. Prior to joining Endo, Mr. Degnan spent more than 10 years at AstraZeneca plc, a global biopharmaceutical company, in roles of increasing responsibility which culminated in the position of Senior Finance Director, U.S. Commercial Finance.
Board of Directors